0001415889-24-018443.txt : 20240628 0001415889-24-018443.hdr.sgml : 20240628 20240628163051 ACCESSION NUMBER: 0001415889-24-018443 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240626 FILED AS OF DATE: 20240628 DATE AS OF CHANGE: 20240628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lichter Jay CENTRAL INDEX KEY: 0001376355 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40475 FILM NUMBER: 241086196 MAIL ADDRESS: STREET 1: C/O ARATANA THERAPEUTICS, INC. STREET 2: 11400 TOMAHAWK CREEK PARKWAY, SUITE 340 CITY: LEAWOOD STATE: KS ZIP: 66211 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Janux Therapeutics, Inc. CENTRAL INDEX KEY: 0001817713 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822289112 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 751-4493 MAIL ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-06282024_040646.xml X0508 4 2024-06-26 0001817713 Janux Therapeutics, Inc. JANX 0001376355 Lichter Jay C/O JANUX THERAPEUTICS, INC. 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130 true false true false 0 Common Stock 2024-06-26 4 A 0 2500 0 A 7083 D Common Stock 3271216 I By Avalon Ventures XI, L.P. Common Stock 633673 I By Avalon BioVentures I, LP Common Stock 3340018 I By Avalon BioVentures SPV I, L.P. Stock Option (right to buy) 39.80 2024-06-26 4 A 0 8350 0 A 2034-06-25 Common Stock 8350 8350 D Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. The shares are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any. The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. /s/ Maria Dobek, Attorney-in-Fact 2024-06-27